Regal Partners Ltd Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Regal Partners Ltd raised its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 22.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,177,601 shares of the biopharmaceutical company’s stock after purchasing an additional 217,774 shares during the period. Royalty Pharma makes up about 3.2% of Regal Partners Ltd’s investment portfolio, making the stock its 11th largest holding. Regal Partners Ltd owned 0.20% of Royalty Pharma worth $31,053,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Swedbank AB increased its holdings in Royalty Pharma by 30.6% in the 2nd quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company’s stock worth $285,151,000 after buying an additional 2,533,570 shares in the last quarter. Norges Bank bought a new stake in shares of Royalty Pharma during the 4th quarter valued at $119,740,000. Homestead Advisers Corp raised its holdings in Royalty Pharma by 40.7% during the first quarter. Homestead Advisers Corp now owns 1,892,540 shares of the biopharmaceutical company’s stock valued at $57,502,000 after acquiring an additional 547,000 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Royalty Pharma by 10.4% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,856,998 shares of the biopharmaceutical company’s stock worth $56,396,000 after purchasing an additional 175,261 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Royalty Pharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,770,988 shares of the biopharmaceutical company’s stock worth $49,747,000 after buying an additional 122,084 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on RPRX shares. Morgan Stanley increased their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research note on Monday, June 3rd. The Goldman Sachs Group lifted their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Stock Down 0.5 %

Shares of NASDAQ RPRX opened at $28.88 on Wednesday. The company has a market cap of $17.14 billion, a P/E ratio of 21.55, a PEG ratio of 4.28 and a beta of 0.46. The firm has a 50-day simple moving average of $27.46 and a two-hundred day simple moving average of $28.19. Royalty Pharma plc has a 1 year low of $25.20 and a 1 year high of $31.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 9.35 and a quick ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. During the same quarter last year, the business posted $0.85 EPS. Research analysts anticipate that Royalty Pharma plc will post 4.04 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Friday, August 16th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 2.91%. Royalty Pharma’s payout ratio is 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.